We have had a pretty decent run on no news.... My two thoughts are someone in the "know" believes a buyout is imminent or someone thinks onxx will surprise to the upside on next earnings. I personally don't think the latter will materialize, so that leaves me thinking a buyout is in the works!
We have indication of potential good sales from kyprolis. And impending regorafenib approval by end of Oct. With present nexavar and good kyprolis sales alone, 90$ target is reasonable. With regorafenib approval news pending by end of Oct and 5 phase 3 trials due to report results by end of year, there is high chance additional good news results...and finally we have potential buyout...the risk/reward for hedge funds, other institutional favors buying...I am now looking for 100+ before end of year.